Literature DB >> 31544563

Chimeric antigen receptor T cells for treatment of transformed Waldenström macroglobulinemia.

Rajat Bansal1, Joseph G Jurcic1, Ahmed Sawas1, Markus Y Mapara1, Ran Reshef1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31544563     DOI： 10.1080/10428194.2019.1665668

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


× No keyword cloud information.
  3 in total

1.  Nanoparticle T-cell engagers as a modular platform for cancer immunotherapy.

Authors:  Kinan Alhallak; Jennifer Sun; Katherine Wasden; Nicole Guenthner; Julie O'Neal; Barbara Muz; Justin King; Daniel Kohnen; Ravi Vij; Samuel Achilefu; John F DiPersio; Abdel Kareem Azab
Journal:  Leukemia       Date:  2021-01-21       Impact factor: 11.528

2.  Histologic Transformation in an Untreated Waldenstrom's Macroglobulinemia After 14 Years: Case Report and Review of the Literature.

Authors:  Elizabeth B Elimimian; Nadeem Bilani; Maria J Diacovo; Skirmante Sirvaitis; Chieh Lin Fu
Journal:  J Hematol       Date:  2021-02-06

3.  CD19-directed chimeric antigen receptor T cell therapy in Waldenström macroglobulinemia: a preclinical model and initial clinical experience.

Authors:  M Lia Palomba; David Qualls; Sebastien Monette; Shenon Sethi; Ahmet Dogan; Mikhail Roshal; Brigitte Senechal; Xiuyan Wang; Isabelle Rivière; Michel Sadelain; Renier J Brentjens; Jae H Park; Eric L Smith
Journal:  J Immunother Cancer       Date:  2022-02       Impact factor: 13.751
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.